Search Results

(E)-Methyl 4-coumarate 100 mg  | 99.59%

TargetMol

(E)-Methyl 4-coumarate (OMpCA) is a predicted metabolite generated by BioTransformer1 that is produced by the metabolism of methyl 3-phenylprop-2-enoate.

More Information Supplier Page

Isosilybin 10 mg  | 100.00%

TargetMol

Isosilybin and Silybin might be suitable candidates to design potent PXR antagonists to prevent drug-drug interactions via CYP3A4 in cancer patients.

More Information Supplier Page

Isosilybin 5 mg  | 100.00%

TargetMol

Isosilybin and Silybin might be suitable candidates to design potent PXR antagonists to prevent drug-drug interactions via CYP3A4 in cancer patients.

More Information Supplier Page

BTZ043 5 mg  | 99.69%

TargetMol

BTZ043 is a DprE1 inhibitor with nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.

More Information Supplier Page

BTZ043 50 mg  | 99.69%

TargetMol

BTZ043 is a DprE1 inhibitor with nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.

More Information Supplier Page

BTZ043 10 mg  | 99.69%

TargetMol

BTZ043 is a DprE1 inhibitor with nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.

More Information Supplier Page

BTZ043 100 mg  | 99.69%

TargetMol

BTZ043 is a DprE1 inhibitor with nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.

More Information Supplier Page

PLX8394 5 mg  | 100.00%

TargetMol

PLX8394 is an orally active inhibitor of serine/threonine-protein kinase B-Raf (BRAF) protein. PLX8394 can selectively bind to and inhibit the activity of both wild-type and mutated forms of BRAF, then inhibit the proliferation of tumor cells which express mutated forms of BRAF. PLX8394 appears to be effective against tumors that express multiple mutated forms of […]

More Information Supplier Page

PLX8394 50 mg  | 100.00%

TargetMol

PLX8394 is an orally active inhibitor of serine/threonine-protein kinase B-Raf (BRAF) protein. PLX8394 can selectively bind to and inhibit the activity of both wild-type and mutated forms of BRAF, then inhibit the proliferation of tumor cells which express mutated forms of BRAF. PLX8394 appears to be effective against tumors that express multiple mutated forms of […]

More Information Supplier Page